Sangamo Announces AAV Capsid Data

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

NEW YORK & BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 12, 2021-- Pfizer Inc. (NYSE: PFE) and   Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy